Atlas Genetics raises £16.9m for market entry of Chlamydia-diagnostics


Bristol – Atlas Genetics has raised £16.9m from a syndicate of new and existing investors led by Novartis Venture Funds, and Consort Medical plc. The series B round will be drawn down over three years to help to commercialize infectious disease tests, especially the global launch of the Velox diagnostic-kit for Chlamydia and gonorrhea. Commercial launch of the system is planned for 2012. The money will also be used for the development of other infectious disease tests and to expand the immunoassay capability of the Velox system.
Velox is a point of care-diagnostic system for a broad range of infectious diseases using either nucleic acid or immuno-assays. Atals’s CEO John Clarkson commented: “We are delighted to welcome the new investors at this time when the company’s first productn is being transferred to manufacture and the core capabilities of the sensor chemistry are being expanded.“
The new investors in this series B financing are Novartis Venture Funds, LSP (Life Sciences Partners), BB Biotech Ventures and Johnson & Johnson Development Corporation. The newly announced financing follows a £1.5 million round in February 2011 supported by Consort Medical plc and other investors. The Company has been funded previously, and continues to be supported, by YFM Equity Partners, Braveheart Investment Group, Wyvern Asset Management, the Crescent Seedcorn Fund and private investors.



London – UK-headquartered pharma major AstraZeneca and Heptares Therapeutics have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors...



London – The UK’s Medical Research Council (MRC) and Technology Strategy Board will jointly invest more than EUR3.5m to fund seven research projects focused on personalised medicine. Four projects will focus on the development of...



Oxford – Oxford BioMedica plc joins forces with ImaginAb, Inc, a specialist in the development of engineered antibody fragments for diagnostic imaging. Under the terms of a research agreement announced yesterday, the US firm will...



London - British Scientists have identified a key enzyme responsible for destroying lung tissue in tuberculosis (TB), they reported in the Journal of Clinical Investigation (Vol. 121, N. 5, May 2011). The results could rapidly...



Cambridge(UK)/ Dublin (USA – British cancer specialist Astex Therapeutics Ltd and US firm SuperGen, Inc. will merge the two companies, if SuperGen’s shareholders confirm the fusion under the new name Astex Pharmaceuticals, Inc....



London/New York – Doctors consulting, speaking or researching for the right pharma companies receive around US$10,000 on average for their services. Three manufacturers obligated by law to publish their payments to US doctors...



London – A new project led by the Wellcome Trust Sanger Institute and the National Health Service will analyse the genomes of up to 12,000 children with physical and mental developmental problems and multiple birth malformations...



London – A £100m (EUR113.4m) investment in research infrastructure and measures to streamline clinical trials were highlights for scientists in the United Kingdom’s 2011–12 budget, which was announced on March 23rd. The boost –...

Displaying results 41 to 50 out of 396

< Previous 41-50 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%


  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%


  • SYNGENTA430.80 CHF32.0%
  • EVOLVA1.84 CHF20.3%
  • BASILEA132.00 CHF16.7%


  • CYTOS0.66 CHF-32.7%
  • MEDIGENE8.43 EUR-19.3%
  • 4SC4.65 EUR-10.6%


  • WILEX3.95 EUR393.7%
  • FORMYCON28.39 EUR318.7%
  • 4SC4.65 EUR307.9%


  • MOLOGEN5.05 EUR-52.5%
  • PAION2.54 EUR-26.8%
  • BIOFRONTERA2.29 EUR-25.6%

No liability assumed, Date: 28.05.2015

Current issue

All issues